No Data
No Data
Tibet Weixinkang Pharmaceutical (603676.SH): "Mannitol Fructose Injection" approved for clinical trials.
Tibet Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary, Inner Mongolia Baiyi Pharmaceutical Co., Ltd. has acquired...
Tibet Weixinkang Pharmaceutical (603676.SH): Subsidiary obtains registration certificate for multiple trace element injection (III) pharmaceuticals.
On July 16th, Gelunhui announced that Tibet Weixinkang Pharmaceutical (603676.SH), its wholly-owned subsidiary Yangpu Jingtai Pharmaceutical Co., Ltd. (referred to as Yangpu Jingtai), has received the Drug Registration Certificate for multiple trace element injections (Ⅲ) approved and issued by the National Medical Products Administration. Multiple trace element injections (Ⅲ) are a trace element supplement used to meet the basic and intermediate needs of patients for trace elements during intravenous nutrition.
Tibet Weixinkang Pharmaceutical (603676.SH) will pay a dividend of 0.285 yuan per share in 2023, with the share registration date on July 1st.
Tibet Weixinkang pharmaceutical (603676.SH) released an announcement that the company will implement annual equity distribution in 2023, distributing a dividend of per share...
Tibet Weixinkang Pharmaceutical (603676.SH): Subsidiary obtains registration certificate for aspartate potassium and magnesium injection.
On June 3rd, Gelonhui announced that Tibet Weixinkang Pharmaceutical (603676.SH) has received the Drug Registration Certificate issued by the State Food and Drug Administration for Magnesium Potassium Aspartate injection. Magnesium Potassium Aspartate injection is an electrolyte supplement drug used for hypokalemia, ventricular arrhythmias caused by digitalis poisoning, sequelae of myocarditis, congestive heart failure, and as an adjuvant therapy for myocardial infarction.
Wei Xinkang (603676.SH): Some directors and senior management plan to reduce their share holdings
Ge Longhui, May 21丨Wei Xinkang (603676.SH) announced that due to personal capital requirements, Mr. Liu Feng plans to reduce the number of company shares held by no more than 954,280 shares through centralized bidding on the Shanghai Stock Exchange within 3 months after 15 trading days from the date of disclosure of this announcement, with a reduction ratio of no more than 0.22% of the company's total shares; due to personal capital requirements, Ms. Liu Binbin plans to reduce the company's holdings through centralized bidding on the Shanghai Stock Exchange within 3 months after 15 trading days from the disclosure of this announcement The number of shares shall not exceed 221,
Wei Xinkang (603676.SH): Does not involve synthetic biotechnology
Gelonghui, May 9丨Wei Xinkang (603676.SH) said on the investor interactive platform that the company's main business is R&D, production, and sales of chemical preparations and their APIs, and is currently not involved in synthetic biotechnology.
No Data